DE602004015498D1 - Substituierte pyrazole als ppar-agonisten - Google Patents
Substituierte pyrazole als ppar-agonistenInfo
- Publication number
- DE602004015498D1 DE602004015498D1 DE602004015498T DE602004015498T DE602004015498D1 DE 602004015498 D1 DE602004015498 D1 DE 602004015498D1 DE 602004015498 T DE602004015498 T DE 602004015498T DE 602004015498 T DE602004015498 T DE 602004015498T DE 602004015498 D1 DE602004015498 D1 DE 602004015498D1
- Authority
- DE
- Germany
- Prior art keywords
- substituted pyrazole
- ppar agonists
- ppar
- agonists
- pyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0326747A GB0326747D0 (en) | 2003-11-17 | 2003-11-17 | Chemical compounds |
| GB0329462A GB0329462D0 (en) | 2003-12-19 | 2003-12-19 | Chemical compounds |
| PCT/EP2004/012965 WO2005049578A1 (en) | 2003-11-17 | 2004-11-15 | Substituted pyrazoles as ppar agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004015498D1 true DE602004015498D1 (de) | 2008-09-11 |
Family
ID=34621661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004015498T Expired - Fee Related DE602004015498D1 (de) | 2003-11-17 | 2004-11-15 | Substituierte pyrazole als ppar-agonisten |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080021030A1 (https=) |
| EP (1) | EP1685113B1 (https=) |
| JP (1) | JP2007511485A (https=) |
| AR (1) | AR046625A1 (https=) |
| AT (1) | ATE402926T1 (https=) |
| DE (1) | DE602004015498D1 (https=) |
| ES (1) | ES2311179T3 (https=) |
| TW (1) | TW200526588A (https=) |
| WO (1) | WO2005049578A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1980912A (zh) * | 2004-07-01 | 2007-06-13 | 第一制药株式会社 | 吡唑衍生物 |
| BRPI0609178A2 (pt) * | 2005-02-28 | 2016-08-23 | Nippon Chemiphar Co | composto ou um sal do mesmo, e, ativador para o receptor ativado do proliferador de peroxissoma delta |
| BRPI0612287A8 (pt) * | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
| CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| US20100056595A1 (en) * | 2007-04-11 | 2010-03-04 | Glaxo Group Limited | Pyrazole Derivatives as P2X7 Modulators |
| EP2277874B1 (en) | 2008-04-15 | 2018-06-27 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor |
| MX2011005221A (es) * | 2008-11-21 | 2011-08-03 | Raqualia Pharma Inc | Nuevo derivado de la pirazol-3-carboxamida que tiene actividad de antagonista del receptor de 5-ht2b. |
| US20110034469A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Heterocyclic Compound |
| BR112012014683B1 (pt) | 2009-12-15 | 2017-11-07 | Bayer Cropscience Ag | Process for the production of 5-pyrazolcarboxylic acid derivatives 1-alkyl- / 1-aryl-substituted and compound acid |
| TWI508968B (zh) | 2010-02-08 | 2015-11-21 | Biota Scient Management | 用於治療呼吸道融合性病毒感染的化合物 |
| CN102918034B (zh) | 2010-03-30 | 2015-06-03 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| CN101870676B (zh) * | 2010-06-24 | 2011-09-07 | 山东大学 | 1-(2-肟基-2-苯基乙基)-3-苯基-1h-吡唑-5-甲酸乙酯衍生物及其制备与应用 |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| LT2968297T (lt) | 2013-03-15 | 2019-01-10 | Verseon Corporation | Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| CN106687445A (zh) | 2014-09-17 | 2017-05-17 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| RU2017131562A (ru) | 2015-02-27 | 2019-03-27 | Версеон Корпорейшн | Замещенные пиразольные соединения как ингибиторы сериновых протеаз |
| DK3464271T3 (da) | 2016-05-31 | 2020-06-15 | Kalvista Pharmaceuticals Ltd | Pyrazolderivater som plasma-kallikreininhibitorer |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| EP3500286A4 (en) | 2016-08-16 | 2020-03-25 | Stealth BioTherapeutics Corp | N-CARBOXYANHYDRIDE-BASED SCALE SYNTHESIS OF ELAMIPRETID |
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| PT3716952T (pt) | 2017-11-29 | 2022-04-14 | Kalvista Pharmaceuticals Ltd | Formas de administração que incluem um inibidor de calicreína plasmática |
| TWI805699B (zh) | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| EP3778593A4 (en) | 2018-04-04 | 2021-12-22 | Japan Tobacco Inc. | HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE |
| JP2021528405A (ja) * | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3621775A1 (de) * | 1986-03-13 | 1988-01-07 | Thomae Gmbh Dr K | Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| WO1999018066A1 (en) * | 1997-10-02 | 1999-04-15 | Sankyo Company, Limited | Amidocarboxylic acid derivatives |
| IL149493A0 (en) * | 1999-11-10 | 2002-11-10 | Takeda Chemical Industries Ltd | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| JP3372923B2 (ja) * | 2000-02-25 | 2003-02-04 | エヌイーシーマイクロシステム株式会社 | 半導体集積回路 |
| EP1480957A1 (en) * | 2002-03-01 | 2004-12-01 | Smithkline Beecham Corporation | Hppars activators |
-
2004
- 2004-11-12 TW TW093134800A patent/TW200526588A/zh unknown
- 2004-11-15 WO PCT/EP2004/012965 patent/WO2005049578A1/en not_active Ceased
- 2004-11-15 AT AT04818779T patent/ATE402926T1/de not_active IP Right Cessation
- 2004-11-15 US US10/595,868 patent/US20080021030A1/en not_active Abandoned
- 2004-11-15 AR ARP040104209A patent/AR046625A1/es unknown
- 2004-11-15 EP EP04818779A patent/EP1685113B1/en not_active Expired - Lifetime
- 2004-11-15 ES ES04818779T patent/ES2311179T3/es not_active Expired - Lifetime
- 2004-11-15 JP JP2006538823A patent/JP2007511485A/ja active Pending
- 2004-11-15 DE DE602004015498T patent/DE602004015498D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1685113A1 (en) | 2006-08-02 |
| ATE402926T1 (de) | 2008-08-15 |
| US20080021030A1 (en) | 2008-01-24 |
| EP1685113B1 (en) | 2008-07-30 |
| JP2007511485A (ja) | 2007-05-10 |
| WO2005049578A1 (en) | 2005-06-02 |
| ES2311179T3 (es) | 2009-02-01 |
| AR046625A1 (es) | 2005-12-14 |
| TW200526588A (en) | 2005-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004015498D1 (de) | Substituierte pyrazole als ppar-agonisten | |
| ATE377419T1 (de) | Substituierte 4-alkoxyoxazol derivate als ppar agonisten | |
| ATE341543T1 (de) | Pyridinoylpiperidine als 5-ht1f agonisten | |
| DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
| DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
| DE60308670D1 (de) | Substituierte indole als alpha-1 agonisten | |
| IL175139A0 (en) | Phenyl derivatives as ppar agonists | |
| ATE504559T1 (de) | Arylanilinderivate als agonisten des beta2- adrenergen rezeptors | |
| DE602004019208D1 (de) | Neue benzimidazolderivate | |
| DE602004019555D1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone | |
| DE50307914D1 (de) | Substituierte benzoylderivate als herbizide | |
| DE602005015204D1 (de) | Oxadiazolonderivate als ppar-delta-agonisten | |
| DE602004004295D1 (de) | 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel | |
| NL1027545A1 (nl) | Chinolonen als antibacteriele middelen. | |
| ATE365161T1 (de) | Pyrazolverbindungen | |
| ATE394372T1 (de) | G-lactamderivate als prostaglandinagonisten | |
| ATE410428T1 (de) | Pyrroloä2,1-cüä1,4übenzodiazepine als vasopressin-agonisten | |
| DE502004005180D1 (de) | Stereomikroskop | |
| NL1024983A1 (nl) | Morfolinen als dopamineagonisten. | |
| ATE364601T1 (de) | Substituierte pyrazolverbindungen | |
| EP1687399A4 (en) | MODIFIED LUCIFERASE | |
| NL1025542A1 (nl) | Geanelleerde heteroarylcarbonzuren als PPAR-agonisten. | |
| FI20035067L (fi) | Parveke tai vastaava | |
| ATE459618T1 (de) | 3-piperidinylisochroman-5-ole als dopaminagonisten | |
| DK1633719T3 (da) | Substituerede spirobenzazepiner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |